Cargando…
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
BACKGROUND: Multiple sclerosis (MS) is a disabling autoimmune demyelinating disorder affecting young people and causing significant disability. In the last decade, different microRNA (miRNA) expression patterns have been associated to several treatment response therapies such as interferon and glati...
Autores principales: | Gonzalez-Martinez, Alicia, Patel, Rohit, Healy, Brian C., Lokhande, Hrishikesh, Paul, Anu, Saxena, Shrishti, Polgar-Turcsanyi, Mariann, Weiner, Howard L., Chitnis, Tanuja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227972/ https://www.ncbi.nlm.nih.gov/pubmed/37254147 http://dx.doi.org/10.1186/s12974-023-02811-z |
Ejemplares similares
-
Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023) -
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021) -
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022) -
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023) -
Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)